The use of Adriamycin and mehtotrexate in carcinoma of the cervix. The development of a safe effective regimen.
The results of treating 59 patients with advanced carcinoma of the cervix with Adriamycin and methotrexate are given. Five combinations of the two cytotoxic drugs have been evaluated, differing only with regard to the methotrexate. One particular regimen has been shown to be effective with a relatively high remission rate coupled with a low rate of side effects.
D000505:Alopecia / Q000139:chemically induced; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D007970:Leukopenia / Q000139:chemically induced; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D009059:Mouth Diseases / Q000139:chemically induced; D012075:Remission, Spontaneous; D013651:Taste Disorders / Q000139:chemically induced; D014456:Ulcer / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D004317:Doxorubicin; D002955:Leucovorin; D008727:Methotrexate